Evaluation of Retinal and Vascular Features in Coats Disease After Intravitreal Injections of Ranibizumab

Study Overview
=================
Brief Summary
-----------------
This study evaluates the retinal and vascular features in patients affected by Coats disease under the effects of Ranibizumab intravitreal injections using optical coherence tomography and optical coherence tomography angiography

Detailed Description
-----------------
Coats disease is an idiopathic retinal vascular disorder, occurs in young males, and is characterized by retinal telangiactasias, numerous yellowish exudates in the subretinal space, macular edema, hemorrhages and, in advanced end-stage, by exudative retinal detachment. Ranibizumab is a vascular endothelial growth factor antagonist represent an efficacy treatment acting on vascular hyperpermeability. The optical coherence tomography and optical coherence tomography angiography represent novel and non-invasive diagnostic techniques that allow a detailed analysis of retinal and vascular features. The study evaluates the changes in optical coherence tomography and optical coherence tomography angiography parameters at baseline and after three monthly injections of Ranibizumab in Coats disease.

Official Title
-----------------
Optical Coherence Tomography Angiography Findings After Intravitreal Ranibizumab in Patients With Coats Disease

Conditions
-----------------
Coats Disease

Intervention / Treatment
-----------------
* Drug: Ranibizumab Injection


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: age older than 18 years diagnosis of Coats disease treatment-naïve with Ranibizumab absence of other vitreoretinal and vascular retinal diseases absence of diabetes Exclusion Criteria: age younger than 18 years No diagnosis of Coats disease previous treatments with Ranibizumab presence of vitreoretinal and vascular retinal diseases presence of diabetes

Ages Eligible for Study
-----------------
Minimum Age: 19 Years
Maximum Age: 30 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Ranibizumab Injection|Ranibizumab Injection (0.5 mg/0.05 ml): Three monthly intravitreal injections|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Study of retinal and vascular features in Coats disease after intravitreal injections of Ranibizumab | The effectiveness of Ranibizumab injections for treating Coats disease using optical coherence tomography (OCT). The parameters analyzed by OCT were: Central Macular Thickness (micron), Subfoveal Choroidal Thickness (micron) | Three months | 
| Study of retinal and vascular features in Coats disease after intravitreal injections of Ranibizumab | The effectiveness of Ranibizumab injections for treating Coats disease using optical coherence tomography angiography (OCTA) The parameters analyzed by OCTA were: retinal vessel density (%), choriocapillaris vessel density (%) | Three months |